Author
Martin Roberge
Director, Development & Innovation
Join Martin Roberge, PhD, Director of Development & Innovation at Cerba Research, as he shares a real-world case study and practical strategies to address high rates of pre-existing antibodies, method validation hurdles, and assay sensitivity optimization in ADC clinical trials.
Gain actionable insights into adapting ADA assay design to the unique demands of next-generation drug modalities and learn valuable lessons that can inform your own approach to complex biologic drug development.
"*" indicates required fields